Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
ConclusionTreatment for 24 weeks with empagliflozin, in contrast to pioglitazone, was associated with improvement of liver steatosis and fibrosis in patients with NAFLD and T2DM. In addition, body weight and abdominal fat area were decreased in the empagliflozin group.Trial RegistrationIranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Actos | Alcoholism | Clinical Trials | DEXA Scan | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fatty Liver Disease (FLD) | Insulin | Jardiance | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | PET Scan | Urology & Nephrology